Market Overview

UPDATE: Stifel Nicolaus Cuts PT to Rigel Pharmaceuticals on Model Changes Post Data

Related RIGL
InterMune's Roche Deal Sends Peer Group Up
Morning Market Losers

Stifel Nicolaus reiterated its Buy rating on Rigel Pharmaceuticals (NASDAQ: RIGL) but reduced its price target from $13 to $11.

Stifel Nicolaus commented, "Rigel's development/collaboration partner AstraZeneca provided top-line results from the P2b OSKIRA-4 study evaluating fostamatinib vs. placebo vs. Humira. … We've lowered our peak sales estimates (now $1.5-1.7 billion) to reflect both increased competitive risk and a more-modest adoption curve amongst the majority of rheumatologists seemingly still prioritizing safety/experience over convenience (Pfizer's TNF-like pricing of tofacitinib likely won't help here either). We believe today's price-action implies too-steep of a risk-adjustment into P3 OSKIRA data and we remain Buy-rated."

Rigel Pharmaceuticals closed at $5.51 on Thursday.

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (RIGL)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters